Clinical Trial Update: Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors [Phase 2]

View source ↗

Summary

Phase 2 results update on Gefitinib for patients with recurrent or progressive brain and central nervous system tumors. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Central Nervous System Neoplasms

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Brain and Central Nervous System Tumors | Phase 2 | Status: COMPLETED